Like most drugs, the development interruption of ADCs is typically due to a lack of efficacy, safety issues, commercial considerations, or a combination of these factors. Since 2000, among the 97 ADCsRead More…
The Future of ADC: Where to Go?
In 1913, the renowned German chemist Paul Ehrlich introduced the concept of the “magic bullet”, which is considered the earliest description of ADC drugs. In 2000, the FDA approved Mylotarg, the firstRead More…
ADC Change: The Re-evolution of Treatment Patterns
Reviewing the 100-year development history of tumor therapy, it has gone through three revolutions, and also led to the revolution of chemotherapy, targeted therapy. and immunotherapy. It can be said that changeRead More…
The Origin of ADC
There are more than 650 active traditional ADC drugs currently, with only 14 having been approved to enter the market, and nearly 200 products still in different clinical research stages. Among them,Read More…
1.7 billion dollars! Bayer Works with Bicycle to Develop Radiation Conjugate Drugs
Bayer and Bicycle Therapeutics announced a strategic partnership agreement to develop, manufacture and commercialize targeted radiation conjugate drugs in the field of oncology using Bicycle Therapeutics’s synthetic peptide technology. Targeted radiotherapy isRead More…
Pfizer Invests 43 Billion Dollars to Buy Seagen!
Recently, Pfizer announced that it would buy Seagen for $229 a share in cash, for a total price of about $43 billion. According to the company’s website, Seagen currently has three ADCRead More…
Uptake and Potential Toxicity Mechanism of Non-Target-Dependent ADC—III
Receptor-mediated Uptake Mechanism The target-dependent uptake and toxicity of ADC can also be mediated by different receptors that recognize the Fc (fragment crystallization) region of the IgG part of ADC. The constantRead More…
Uptake and Potential Toxicity Mechanism of Non-Target-Dependent ADC—II
Nonspecific endocytosis Endocytosis is an important process in cell uptake of nutrients, regulation of transmembrane kinetics, synaptic vesicle recycling, and so on. Endocytosis can also play an important role in the uptakeRead More…
Uptake and Potential Toxicity Mechanism of Non-Target-Dependent ADC—I
Linker-Unstable Payload Connection Connector-payload instability can cause the payload to be released prematurely into the bloodstream and lead to ADC miss toxicity. The choice of connectors is one of the main driversRead More…
Non-targeted ADC Uptake Matters!
So far, a total of 16 ADC drugs have been approved worldwide, and one (trastuzumab duocarmazine) is still in the stage of applying for listing. In recent years, with the significant increaseRead More…